{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T07:46:20Z","timestamp":1777794380062,"version":"3.51.4"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2015,7,10]],"date-time":"2015-07-10T00:00:00Z","timestamp":1436486400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Pharm"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1007\/s11096-015-0159-3","type":"journal-article","created":{"date-parts":[[2015,10,24]],"date-time":"2015-10-24T21:45:47Z","timestamp":1445723147000},"page":"1095-1103","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Change in prescription pattern as a potential marker for adverse drug reactions of angiotensin converting enzyme inhibitors"],"prefix":"10.1007","volume":"37","author":[{"given":"Seyed Hamidreza","family":"Mahmoudpour","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Folkert W.","family":"Asselbergs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine E.","family":"de Keyser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick C.","family":"Souverein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Albert","family":"Hofman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno H.","family":"Stricker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthonius","family":"de Boer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anke-Hilse","family":"Maitland-van der Zee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,7,10]]},"reference":[{"key":"159_CR1","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1161\/01.CIR.97.14.1411","volume":"97","author":"NJ Brown","year":"1998","unstructured":"Brown NJ, Vaughan DE. Angiotensin-converting enzyme inhibitors. Circulation. 1998;97:1411\u201320.","journal-title":"Circulation"},{"key":"159_CR2","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s10557-012-6424-y","volume":"27","author":"TG Lueder von","year":"2013","unstructured":"von Lueder TG, Krum H. RAAS inhibitors and cardiovascular protection in large scale trials. Cardiovasc Drugs Ther. 2013;27:171\u20139.","journal-title":"Cardiovasc Drugs Ther"},{"key":"159_CR3","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1586\/erc.13.42","volume":"11","author":"R Ferrari","year":"2013","unstructured":"Ferrari R, Boersma E. The impact of ACE inhibition on all-cause and cardiovascular mortality in contemporary hypertension trials: a review. Expert Rev Cardiovasc Ther. 2013;11:705\u201317.","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"159_CR4","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1001\/jamainternmed.2014.348","volume":"174","author":"J Cheng","year":"2014","unstructured":"Cheng J, Zhang W, Zhang X, Han F, Li X, He X, et al. Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis. JAMA Intern Med. 2014;174:773\u201385.","journal-title":"JAMA Intern Med"},{"key":"159_CR5","unstructured":"National Prescription Audit PLUS. IMS.2014. http:\/\/www.imshealth.com . Accessed 1 Dec 2014."},{"key":"159_CR6","unstructured":"The drugs and medical devices Information Project (GIP). https:\/\/www.gipdatabank.nl . Accessed 20 April 2015."},{"key":"159_CR7","unstructured":"Croft K. Prescriptions Dispensed in the Community England 2003-13. Prescribing and Primary Care, Health and Social Care Information Centre; 9 July 2014. 110 p. Available on http:\/\/www.hscic.gov.uk ."},{"key":"159_CR8","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1111\/j.1365-2753.2003.00484.x","volume":"10","author":"T Morimoto","year":"2004","unstructured":"Morimoto T, Gandhi TK, Fiskio JM, Seger AC, So JW, Cook EF, et al. An evaluation of risk factors for adverse drug events associated with angiotensin-converting enzyme inhibitors. J Eval Clin Pract. 2004;10:499\u2013509.","journal-title":"J Eval Clin Pract"},{"key":"159_CR9","doi-asserted-by":"crossref","first-page":"169S","DOI":"10.1378\/chest.129.1_suppl.169S","volume":"129","author":"PV Dicpinigaitis","year":"2006","unstructured":"Dicpinigaitis PV. Angiotensin-converting enzyme inhibitor-induced cough: ACCP evidence-based clinical practice guidelines. Chest. 2006;129:169S\u201373S.","journal-title":"Chest"},{"key":"159_CR10","doi-asserted-by":"crossref","first-page":"72","DOI":"10.2165\/00002018-199615010-00006","volume":"15","author":"A Overlack","year":"1996","unstructured":"Overlack A. ACE inhibitor-induced cough and bronchospasm. Incidence, mechanisms and management. Drug Saf. 1996;15:72\u20138.","journal-title":"Drug Saf"},{"key":"159_CR11","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1007\/BF03022528","volume":"53","author":"P Sarkar","year":"2006","unstructured":"Sarkar P, Nicholson G, Hall G. Brief review: angiotensin converting enzyme inhibitors and angioedema: anesthetic implications. Can J Anaesth. 2006;53:994\u20131003.","journal-title":"Can J Anaesth"},{"key":"159_CR12","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1097\/01.hjh.0000226211.95936.f5","volume":"24","author":"TA Burke","year":"2006","unstructured":"Burke TA, Sturkenboom MC, Lu SE, Wentworth CE, Lin Y, Rhoads GG. Discontinuation of antihypertensive drugs among newly diagnosed hypertensive patients in UK general practice. J Hypertens. 2006;24:1193\u2013200.","journal-title":"J Hypertens"},{"key":"159_CR13","first-page":"609","volume":"17","author":"S Vegter","year":"2011","unstructured":"Vegter S, Nguyen NH, Visser ST, de Jong-van den Berg LT, Postma MJ, Boersma C. Compliance, persistence, and switching patterns for ACE inhibitors and ARBs. Am J Manag Care. 2011;17:609\u201316.","journal-title":"Am J Manag Care"},{"key":"159_CR14","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1007\/s11096-008-9264-x","volume":"31","author":"DB Wieren-de Wijer van","year":"2009","unstructured":"van Wieren-de Wijer DB, Maitland-van der Zee AH, de Boer A, Stricker BH, Kroon AA, de Leeuw PW, et al. Recruitment of participants through community pharmacies for a pharmacogenetic study of antihypertensive drug treatment. Pharm World Sci. 2009;31:158\u201364.","journal-title":"Pharm World Sci"},{"key":"159_CR15","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s10654-013-9866-z","volume":"28","author":"A Hofman","year":"2013","unstructured":"Hofman A, Darwish Murad S, van Duijn CM, Franco OH, Goedegebure A, Ikram MA, et al. The Rotterdam Study: 2014 objectives and design update. Eur J Epidemiol. 2013;28:889\u2013926.","journal-title":"Eur J Epidemiol"},{"key":"159_CR16","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1007\/s11096-014-0044-5","volume":"37","author":"VK Patadia","year":"2015","unstructured":"Patadia VK, Schuemie MJ, Coloma P, Herings R, van der Lei J, Straus S, et al. Evaluating performance of electronic healthcare records and spontaneous reporting data in drug safety signal detection. Int J Clin Pharm. 2015;37:94\u2013104.","journal-title":"Int J Clin Pharm"},{"key":"159_CR17","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s40264-013-0024-z","volume":"36","author":"S Vegter","year":"2013","unstructured":"Vegter S, de Boer P, van Dijk KW, Visser S, de Jong-van den Berg LT. The effects of antitussive treatment of ACE inhibitor-induced cough on therapy compliance: a prescription sequence symmetry analysis. Drug Saf. 2013;36:435\u20139.","journal-title":"Drug Saf"},{"key":"159_CR18","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/BF00145007","volume":"7","author":"A Hofman","year":"1991","unstructured":"Hofman A, Grobbee DE, de Jong PT, van den Ouweland FA. Determinants of disease and disability in the elderly: the Rotterdam Elderly Study. Eur J Epidemiol. 1991;7:403\u201322.","journal-title":"Eur J Epidemiol"},{"key":"159_CR19","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1097\/01.hjh.0000186832.41125.8a","volume":"23","author":"G Mazzaglia","year":"2005","unstructured":"Mazzaglia G, Mantovani LG, Sturkenboom MC, Filippi A, Trifiro G, Cricelli C, et al. Patterns of persistence with antihypertensive medications in newly diagnosed hypertensive patients in Italy: a retrospective cohort study in primary care. J Hypertens. 2005;23:2093\u2013100.","journal-title":"J Hypertens"},{"key":"159_CR20","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1111\/j.1365-2710.2011.01300.x","volume":"37","author":"MC Wong","year":"2012","unstructured":"Wong MC, Lau RK, Jiang JY, Griffiths SM. Discontinuation of angiotensin-converting enzyme inhibitors: a cohort study. J Clin Pharm Ther. 2012;37:335\u201341.","journal-title":"J Clin Pharm Ther"},{"key":"159_CR21","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jclinepi.2005.05.005","volume":"59","author":"BL Wijk Van","year":"2006","unstructured":"Van Wijk BL, Klungel OH, Heerdink ER, de Boer A. Refill persistence with chronic medication assessed from a pharmacy database was influenced by method of calculation. J Clin Epidemiol. 2006;59:11\u20137.","journal-title":"J Clin Epidemiol"},{"key":"159_CR22","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1023\/A:1023292830670","volume":"25","author":"AH Maitland-van der Zee","year":"2003","unstructured":"Maitland-van der Zee AH, Klungel OH, Stricker BH, van der Kuip DA, Witteman JC, Hofman A, et al. Repeated nitrate prescriptions as a potential marker for angina pectoris. A comparison with medical information from the Rotterdam Study. Pharm World Sci. 2003;25:70\u20132.","journal-title":"Pharm World Sci"},{"key":"159_CR23","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/pds.1866","volume":"19","author":"ML Becker","year":"2010","unstructured":"Becker ML, Visser LE, van Schaik RH, Hofman A, Uitterlinden AG, Stricker BH. Influence of genetic variation in CYP3A4 and ABCB1 on dose decrease or switching during simvastatin and atorvastatin therapy. Pharmacoepidemiol Drug Saf. 2010;19:75\u201381.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"159_CR24","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/FPC.0000000000000018","volume":"24","author":"CE Keyser de","year":"2014","unstructured":"de Keyser CE, Peters BJ, Becker ML, Visser LE, Uitterlinden AG, Klungel OH, et al. The SLCO1B1 c.521T\u00a0>\u00a0C polymorphism is associated with dose decrease or switching during statin therapy in the Rotterdam Study. Pharmacogenet Genomics. 2014;24:43\u201351.","journal-title":"Pharmacogenet Genomics"},{"key":"159_CR25","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1093\/eurheartj\/ehi825","volume":"27","author":"J Heeringa","year":"2006","unstructured":"Heeringa J, van der Kuip DA, Hofman A, Kors JA, van Herpen G, Stricker BH, et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J. 2006;27:949\u201353.","journal-title":"Eur Heart J"},{"key":"159_CR26","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1002\/pds.3457","volume":"22","author":"B Wettermark","year":"2013","unstructured":"Wettermark B, Zoega H, Furu K, Korhonen M, Hallas J, Norgaard M, et al. The Nordic prescription databases as a resource for pharmacoepidemiological research\u2013a literature review. Pharmacoepidemiol Drug Saf. 2013;22:691\u20139.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"159_CR27","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1007\/s11096-010-9372-2","volume":"32","author":"A Salmeron-Garcia","year":"2010","unstructured":"Salmeron-Garcia A, Cabeza Barrera J, Vergara Pavon MJ, Roman Marquez E, Cortes de Miguel S, Vallejo-Rodriguez I, et al. Detection of adverse drug reactions through the minimum basic data set. Pharm World Sci. 2010;32:322\u20138.","journal-title":"Pharm World Sci"},{"key":"159_CR28","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/j.1365-2125.2009.03571.x","volume":"69","author":"S Vegter","year":"2010","unstructured":"Vegter S, de Jong-van den Berg LT. Misdiagnosis and mistreatment of a common side-effect\u2013angiotensin-converting enzyme inhibitor-induced cough. Br J Clin Pharmacol. 2010;69:200\u20133.","journal-title":"Br J Clin Pharmacol"}],"container-title":["International Journal of Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-015-0159-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11096-015-0159-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-015-0159-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,26]],"date-time":"2019-03-26T19:14:40Z","timestamp":1553627680000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11096-015-0159-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7,10]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["159"],"URL":"https:\/\/doi.org\/10.1007\/s11096-015-0159-3","relation":{},"ISSN":["2210-7703","2210-7711"],"issn-type":[{"value":"2210-7703","type":"print"},{"value":"2210-7711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,7,10]]}}}